A Study Using Risk Factors to Determine Treatment for Children With Favorable Histology Wilms Tumor

Full Title

Risk Adapted Treatment of Unilateral Favorable Histology Wilms Tumors (FHWT) (AREN2231) (CIRB)

Purpose

Wilms tumor the most common type of kidney cancer in children. Favorable tissue (histology) Wilms tumors (FHWT) are the most common subtype.

Large clinical trials have led to the development of treatments that are likely to cure most children with FHWT. However, in some children, the cancer comes back (relapses), and some patients do not survive. Researchers have identified features of FHWT that predict a higher or lower chance of the cancer coming back after treatment.

In this study, researchers are assessing the use of risk factors to determine the best treatment for children with FHWT. They want to see how the results of tumor tissue tests, biological tests, imaging exams, and response to therapy may improve FHWT treatment.

Who Can Join

To join this study, there are a few conditions. You or your child must:

  • Be newly diagnosed stage 1-4 FHWT.
  • Be under age 30.

Contact

For more information about this study or to see if you or your child can join, please call 833-MSK-KIDS.

Protocol

25-301

Phase

Phase III (phase 3)

Disease Status

Newly Diagnosed

Investigator

Co-Investigators

ClinicalTrials.gov ID

NCT06401330